- $2.05bn
- $2.13bn
- $120.25m
Brief: Mesoblast Says FDA Acknowledges Effects On Pain Intensity Favor Rexlemestrocel-L
Brief: Mesoblast Says Ryoncil Sales For Quarter Increase 60% To $35.1M
ASX-shares of Mesoblast rise on strong Ryoncil sales
Brief: Mesoblast Appoints Philip Facchina As Non-Executive Chair
Brief: Mesoblast Expects Gross Revenue Of More Than $30.0 Mln From Sales Of Ryoncil For Quarter Ending Dec 31
Brief: Mesoblast Says James M. O’Brien Appointed Chief Financial Officer
Brief: Mesoblast Appoints James M. O'brien As U.S.-Based CFO
Mesoblast's Australian shares climb as O'Brien becomes finance chief of US division
Brief: Mesoblast To Meet With FDA Next Month To Discuss Rexlemestrocel-L And Opioid Cessation
ASX shares of Mesoblast jump on FDA meeting plans, Phase 3 study update
Brief: Mesoblast Posts Quarter Revenue From Cell Therapy Products $20.6 Million
ASX-listed Mesoblast hits 8-month high; Bell Potter upbeat on Ryoncil revenues
ASX-listed Mesoblast jumps on key drug's quarterly sales surge
Brief: Mesoblast Ltd Posts Gross Revenue Of $21.9 Million On Ryoncil Sales For Quarter
ASX-listed Mesoblast surges on US Medicare billing approval for key drug
Brief: Mesoblast Enters Option To Issue $50 Million Convertible Notes
ASX-listed Mesoblast's shares tank 10% on widening annual loss
Australian healthcare stocks fall most since 2020, dragged lower by CSL
ASX-listed Mesoblast jumps as US FDA paves way for heart failure drug